Personalized oncology meets immunology: The path toward precision immunotherapy

Cancer Discovery

Volumn 6, Issue 7, 2016, Pages 703-713

  Mandal, Rajarsi ^a   Chan, Timothy A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; B7 ANTIGEN; BIOLOGICAL MARKER; CANCER ANTIBODY; CANCER TESTIS ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENOBLITUZUMAB; EPACADOSTAT; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; INDOXIMOD; INTERLEUKIN 2; IPILIMUMAB; LIRILUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; SAMALIZUMAB; SIPULEUCEL T; T LYMPHOCYTE RECEPTOR; URELUMAB; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; BACTEROIDES FRAGILIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GENE MUTATION; GENETIC TRAIT; HISTOLOGY; HUMAN; MELANOMA; METASTATIC MELANOMA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RENAL CANCER CELL LINE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; WART VIRUS; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; GENOMIC INSTABILITY; GENOMICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ONCOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TREATMENT OUTCOME; TRENDS; VIROLOGY;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CANCER VACCINES; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GENOMICS; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; TREATMENT OUTCOME;

EID: 84977564001     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0146     Document Type: Review

References (81)

1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134–144.
2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
3. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–7.
4. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–571.
5. Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: Current evidence. OncoTargets Ther 2014; 7: 1349–1359.
6. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336–347.
7. Zou W, Chen L.Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467–477.
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2465.
9. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dosecomparison cohort of a phase 1 trial. Lancet 2014; 384: 1109–1117.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
11. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020–1030.
12. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65: 1089–1096.
13. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917–927.
14. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187–2194.
15. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specifi c cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536–541.
16. Huard B, Gaulard P, Faure F, Hercend T, Triebel F.Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994; 39: 213–217.
17. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle K J, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182: 6659–6669.
18. Kreimer AR. Prospects for prevention of HPV-driven oropharynx cancer.Oral Oncol 2014; 50: 555–9.
19. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30: F123–F138.
20. Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong ZY, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2014; 209: 1739–1743.
21. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 2014; 20: 822–828.
22. Chemin I. Evaluation of a hepatitis B vaccination program in Taiwan: Impact on hepatocellular carcinoma development. Future Oncol 2010; 6: 21–23.
23. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422.
24. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119–2127.
25. Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Translat Med 2015; 7: 283ra52.
26. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015; 33: 1325–1333.
27. Morgan DA, Ruscetti FW, Gallo R.Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–1008.
28. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4: 127ps8.
29. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550–4557.
30. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infi ltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and effi cacy after failure to prior immunotherapies. Clin Cancer Res 2013; 19: 4792–4800.
31. Ullal AV, Peterson V, Agasti SS, Tuang S, Juric D, Castro CM, et al. Cancer cell profi ling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 2014; 6: 219ra9.
32. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124–128.
33. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400–404.
34. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N.Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160: 48–61.
35. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24: 743–750.
36. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189–2199.
37. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509–2520.
38. Cancer Genome Atlas Research N. Comprehensive molecular profi ling of lung adenocarcinoma. Nature 2014; 511: 543–550
39. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, et al. Deconstructing the peptide-MHC specifi city of T cell recognition. Cell 2014; 157: 1073–1087.
40. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207–211.
41. Voelter V, Rufer N, Reynard S, Greub G, Brookes R, Guillaume P, et al. Characterization of Melan-A reactive memory CD8 + T cells in a healthy donor. Int Immunol 2008; 20: 1087–1096.
42. Brown SD, Raeburn LA, Holt RA.Profi ling tissue-resident T cell repertoires by RNA sequencing. Genome Med 2015; 7: 125
43. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079–1084.
44. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifi dobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084–1089
45. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999; 9: M57–M60.
46. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643–649.
47. Preston BD, Albertson TM, Herr AJ. DNA replication fi delity and cancer. Semin Cancer Biol 2010; 20: 281–293.
48. Shevelev IV, Hubscher U. The 3′ 5′ exonucleases. Semin Cancer Biol 2002; 3: 364–376.
49. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 2009; 106: 17101–17104.
50. Goldsby RE, Hays LE, Chen X, Olmsted EA, Slayton WB, Spangrude GJ, et al. High incidence of epithelial cancers in mice defi cient for DNA polymerase delta proofreading. Proc Natl Acad Sci U S A 2002; 99: 15560–15565.
51. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45: 136–144.
52. Briggs S, Tomlinson I. Germline and somatic polymerase epsilon and delta mutations defi ne a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013; 230: 148–153.
53. Hansen MF, Johansen J, Bjornevoll I, Sylvander AE, Steinsbekk KS, Saetrom P, et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam Cancer 2015; 14: 437–448.
54. Kunkel TA, Bebenek K. DNA replication fidelity. Annu Rev Biochem 2000; 69: 497–529.
55. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 1998; 148: 1667–1686.
56. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008; 17: 3208–3215
57. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044–2058.
58. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol 2014; 12: 1059–1068.
59. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15: 7412–7420.
60. Maple JT, Smyrk TC, Boardman LA, Johnson RA, Thibodeau SN, Chari ST. Defective DNA mismatch repair in long-term (>or = 3 years) survivors with pancreatic cancer. Pancreatology 2005; 5: 220–227; discussion 7–8
61. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.
62. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun 2001; 1: 1.
63. Mamsen LS, Brochner CB, Byskov AG, Mollgard K. The migration and loss of human primordial germ stem cells from the hind gut epithelium towards the gonadal ridge. Int J Dev Biol 2012; 56: 771–778
64. Silva WA Jr, Gnjatic S, Ritter E, Chua R, Cohen T, Hsu M, et al. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun 2007; 7: 18.
65. Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropinbeta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995; 76: 1467–1475.
66. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647.
67. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4 + T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698–2703.
68. Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: Prime candidates for immunotherapy. Oncotarget 2015; 6: 15772–15787.
69. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72: 1081–1091.
70. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348: 803–808.
71. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692–696.
72. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. Nat Med 2015; 21: 81–85.
73. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, C hen X, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 2013; 19: 1534–1541.
74. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350: 1387–1390.
75. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer. Science 2014; 344: 641–645.
76. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
77. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8 + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007; 117: 3383–3392.
78. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245–1252.
79. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492.
80. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and infl uenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 3: 7.
81. Andrews MC, Woods K, Cebon J, Behren A. Evolving role of tumor antigens for future melanoma therapies. Fut Oncol 2014; 10: 1457–1468.